NS2B-NS3pro como Alvo Molecular para o Desenvolvimento de Fármacos contra Dengue

Godói, Isabella Piassi Dias; Taranto, Martinelle Ferreira Rocha; Lima, William Gustavo; Alves, Ricardo José; Comar, Moacyr; Ferreira, Jaqueline Maria Siqueira; Taranto, Alex Gutterres

doi:10.5433/2316-5200.2014v3n2p16

Cited by 2 publications

(1 citation statement)

References 45 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include leukopenia (reduction in white blood cells, hemorrhage (bleeding) and circulatory collapse (shock) associated with deaths [22]. Currently, there is no specific antiviral treatment to manage the dengue virus [23][24][25][26]. At the end of 2015, the Brazilian Government approved the first dengue vaccine (CYD-TDV; Dengvaxia ® ) to prevent DENV infection with a reported global efficacy of 60%, recommended for individuals between 9 and 45 years old [27,28].…”

Section: Introductionmentioning

confidence: 99%

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

Godói

Silva

Sarker

et al. 2018

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was to measure the costs and disease burden of symptomatic dengue infections in Brazil from the perspective of the Brazilian Public Health System (SUS) between 2000 and 2015 using Brazilian public health system databases. Specific age group incidence estimates were used to calculate the disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Areas covered: SUS spent almost USD159 million and USD10 million to treat dengue and severe dengue, respectively, between 2000-2015. This is principally hospitalization costs with the majority of patients self-treated at home with minor symptoms. The average notification rate for dengue was 273 per 100,000 inhabitants and 3 per 100,000 for severe dengue, with annual DALYs estimates ranging between 72.35 to 6,824.45 during the 16 years. Expert commentary: The epidemiological and morbidity burden associated with dengue is substantial in Brazil, with costs affected by the fact that most patients self-treat at home with these costs not included in SUS. The Brazilian government urgently needs to proactively evaluate the real costs and clinical benefits of any potential dengue vaccination program by the National Immunization Program to guide future decision making.

show abstract

Section: Introductionmentioning

confidence: 99%

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

Godói

Silva

Sarker

et al. 2018

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds

et al. 2017

View full text Add to dashboard Cite

Dengue virus (DENV) infection can lead to a wide range of clinical manifestations, including fatal hemorrhagic complications. There is a need to find effective pharmacotherapies to treat this disease due to the lack of specific immunotherapies and antiviral drugs. That said, the DENV NS2B/NS3pro protease complex is essential in both the viral multiplication cycle and in disease pathogenesis, and is considered a promising target for new antiviral therapies. Here, we performed a systematic review to evaluate the pharmacophoric characteristics of promising compounds against NS2B/NS3pro reported in the past 10 years. Online searches in the PUBMED/MEDLINE and SCOPUS databases resulted in 165 articles. Eight studies, which evaluated 3,384,268 molecules exhibiting protease inhibition activity, were included in this review. These studies evaluated anti-dengue activity in vitro and the IC and EC values were provided. Most compounds exhibited non-competitive inhibition. Cytotoxicity was evaluated in BHK-21, Vero, and LLC-MK2 cells, and the CC values obtained ranged from < 1.0 to 780.5 µM. Several groups were associated with biological activity against dengue, including nitro, catechol, halogen and ammonium quaternaries. Thus, these groups seem to be potential pharmacophores that can be further investigated to treat dengue infections.

show abstract

NS2B-NS3pro como Alvo Molecular para o Desenvolvimento de Fármacos contra Dengue

Cited by 2 publications

References 45 publications

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine

Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds

Contact Info

Product

Resources

About